Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Temporal trends in treatment patterns and overall survival for multiple myeloma management in Taiwan using the national health insurance claims database

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShih‐Pei Shen

Discussion

Loading...

Member takes

Overview

Population-based analysis highlights improved survival rates in multiple myeloma due to treatment changes and reimbursements.

Key Points

  • To investigate treatment patterns and overall survival trends for multiple myeloma in Taiwan from 2013 to 2022.
  • Population-based study using the Taiwan National Healthcare Insurance Research database.
  • Included newly diagnosed transplant-ineligible multiple myeloma patients.
  • Overall survival was estimated using Kaplan-Meier methods and hazard ratios from a multivariate Cox regression model.
  • 2151 patients diagnosed with NDMM between 2013–2017, and 2643 between 2018–2022.
  • Significant increase in usage of daratumumab and bortezomib combinations in treatment regimens.
  • Overall survival improved significantly from 2.17 years (2013-2017) to not reached (2021-2022).

Cite This Study

Shih‐Pei Shen (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d054https://doi.org/10.1182/blood-2025-8133
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Survival differences in transplant ineligible multiple myeloma patients in Japan and Taiwan: Exploring the potential influence of timely and unrestricted access to novel therapies2025 · 1 citations
  2. 2Updated analysis of survival and treatment evolution in european multiple myeloma patients (2012–2023) across 7 countries from the honeur network2025
  3. 3Improved survival in patients with multiple myeloma over time: A retrospective single-center study focusing on patients aged 80 years and above2025
  4. 4Survival outcomes of multiple myeloma patients previously exposed to BCMA-targeted therapies in the honeur european network2025
  5. 5Quality of life in multiple myeloma: A scoping review2025